Main Article Content
Aims: Highlight pitolisant as an effective treatment for narcolepsy.
Case Report: We describe two patients treated with pitolisant. Patient A showed decreased daytime sleepiness and improved social functioning. Patient B struggled to find a dose that kept side effects at a minimum.
Discussion: This orphan drug has a unique mechanism of action, that combined with dosing flexibility allows for a treatment option that can better attend to individual differences in patient needs.
Conclusion: The use of pitolisant presents some benefits and challenges, nonetheless offering a promising treatment for narcolepsy.
Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord. 2019;12: 1756286419875622.
Romigi, A, Vitrani G, Lo Giudice T, Centonze, D, Franco V. Profile of pitolisant in the management of narcolepsy: Design, development and place in therapy. Drug Design, Development and Therapy. 2018;12:2665–2675.
Dauvilliers Y, Bassetti C, Lammers GJ et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: A double-blind, randomised trial. Lancet Neurol. 2013; 12(11):1068-75.
Uguen M, Perrin D, Belliard S et al. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil. Br J Pharmacol. 2013;169(3):632-44.
Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: A randomized, double-blind, placebo-controlled trial. Lancet Neurology. 2017; 16(3):200-207.
Setnik B, McDonnell M, Mills C, et al. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep. 2020; 43(4):zsz252.